![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Evaluation of Renal and Bone Safety at 4 Years in Post-Liver Transplant Patients With Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis
|
|
|
EASL 2022 June 22-26 London
Edward J. Gane,1 Rica Dagooc,1 Dominic Ray-Chaudhuri,1 Thomas Mules,1 Frida Abramov,2 Curtis D. Holt,2 Hongyuan Wang,2 Vithika Suri,2 Anu O. Osinusi,2 John F. Flaherty2
1New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 2Gilead Sciences, Inc., Foster City, California, USA
![0706221](../images/070622/070522-8/0706221.gif)
![0706222](../images/070622/070522-8/0706222.gif)
![0706223](../images/070622/070522-8/0706223.gif)
![0706224](../images/070622/070522-8/0706224.gif)
![0706225](../images/070622/070522-8/0706225.gif)
![0706226](../images/070622/070522-8/0706226.gif)
![0706227](../images/070622/070522-8/0706227.gif)
![0706228](../images/070622/070522-8/0706228.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|